Literature DB >> 36189828

Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study.

Marijn Huiskamp1, Svenja Kiljan2, Shanna Kulik2, Maarteen E Witte3, Laura E Jonkman2, John Gjm Bol2, Geert J Schenk2, Hanneke E Hulst4, Prejaas Tewarie5, Menno M Schoonheim2, Jeroen Jg Geurts2.   

Abstract

BACKGROUND: Synaptic and neuronal loss contribute to network dysfunction and disability in multiple sclerosis (MS). However, it is unknown whether excitatory or inhibitory synapses and neurons are more vulnerable and how their losses impact network functioning.
OBJECTIVE: To quantify excitatory and inhibitory synapses and neurons and to investigate how synaptic loss affects network functioning through computational modeling.
METHODS: Using immunofluorescent staining and confocal microscopy, densities of glutamatergic and GABAergic synapses and neurons were compared between post-mortem MS and non-neurological control cases. Then, a corticothalamic biophysical model was employed to study how MS-induced excitatory and inhibitory synaptic loss affect network functioning.
RESULTS: In layer VI of normal-appearing MS cortex, excitatory and inhibitory synaptic densities were significantly lower than controls (reductions up to 14.9%), but demyelinated cortex showed larger losses of inhibitory synapses (29%). In our computational model, reducing inhibitory synapses impacted the network most, leading to a disinhibitory increase in neuronal activity and connectivity.
CONCLUSION: In MS, excitatory and inhibitory synaptic losses were observed, predominantly for inhibitory synapses in demyelinated cortex. Inhibitory synaptic loss affected network functioning most, leading to increased neuronal activity and connectivity. As network disinhibition relates to cognitive impairment, inhibitory synaptic loss seems particularly relevant in MS.

Entities:  

Keywords:  Multiple sclerosis; computational modeling; inhibitory synaptic loss; network function; histopathology

Mesh:

Year:  2022        PMID: 36189828      PMCID: PMC9574900          DOI: 10.1177/13524585221125381

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   5.855


  35 in total

1.  Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study.

Authors:  Alvino Bisecco; Maria A Rocca; Elisabetta Pagani; Laura Mancini; Christian Enzinger; Antonio Gallo; Hugo Vrenken; Maria Laura Stromillo; Massimiliano Copetti; David L Thomas; Franz Fazekas; Gioacchino Tedeschi; Frederik Barkhof; Nicola De Stefano; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2015-04-14       Impact factor: 5.038

2.  Inhibitory connectivity defines the realm of excitatory plasticity.

Authors:  Gianluigi Mongillo; Simon Rumpel; Yonatan Loewenstein
Journal:  Nat Neurosci       Date:  2018-09-17       Impact factor: 24.884

3.  The substrate of increased cortical FA in MS: A 7T post-mortem MRI and histopathology study.

Authors:  Laura E Jonkman; Roel Klaver; Lazar Fleysher; Matilde Inglese; Jeroen Jg Geurts
Journal:  Mult Scler       Date:  2016-03-04       Impact factor: 6.312

4.  Phagocyte-mediated synapse removal in cortical neuroinflammation is promoted by local calcium accumulation.

Authors:  Mehrnoosh Jafari; Adrian-Minh Schumacher; Nicolas Snaidero; Emily M Ullrich Gavilanes; Tradite Neziraj; Virág Kocsis-Jutka; Daniel Engels; Tanja Jürgens; Ingrid Wagner; Juan Daniel Flórez Weidinger; Stephanie S Schmidt; Eduardo Beltrán; Nellwyn Hagan; Lisa Woodworth; Dimitry Ofengeim; Joseph Gans; Fred Wolf; Mario Kreutzfeldt; Ruben Portugues; Doron Merkler; Thomas Misgeld; Martin Kerschensteiner
Journal:  Nat Neurosci       Date:  2021-01-25       Impact factor: 24.884

Review 5.  Immunopathology of multiple sclerosis.

Authors:  Calliope A Dendrou; Lars Fugger; Manuel A Friese
Journal:  Nat Rev Immunol       Date:  2015-08-07       Impact factor: 53.106

6.  Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage.

Authors:  Marco Vercellino; Aristide Merola; Chiara Piacentino; Barbara Votta; Elisabetta Capello; Giovanni Luigi Mancardi; Roberto Mutani; Maria Teresa Giordana; Paola Cavalla
Journal:  J Neuropathol Exp Neurol       Date:  2007-08       Impact factor: 3.685

7.  Enhanced GABAergic Immunoreactivity in Hippocampal Neurons and Astroglia of Multiple Sclerosis Patients.

Authors:  Svenja Kiljan; Marloes Prins; Bart M Baselmans; John G J M Bol; Geert J Schenk; Anne-Marie van Dam
Journal:  J Neuropathol Exp Neurol       Date:  2019-06-01       Impact factor: 3.685

8.  Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS.

Authors:  Deborah N Schoonhoven; Matteo Fraschini; Prejaas Tewarie; Bernard Mj Uitdehaag; Anand Jc Eijlers; Jeroen Jg Geurts; Arjan Hillebrand; Menno M Schoonheim; Cornelis J Stam; Eva Mm Strijbis
Journal:  Mult Scler       Date:  2018-11-22       Impact factor: 6.312

9.  Selective vulnerability of inhibitory networks in multiple sclerosis.

Authors:  Lida Zoupi; Sam A Booker; Dimitri Eigel; Carsten Werner; Peter C Kind; Tara L Spires-Jones; Ben Newland; Anna C Williams
Journal:  Acta Neuropathol       Date:  2021-01-15       Impact factor: 17.088

10.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman
Journal:  Neurology       Date:  2014-05-28       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.